Short-term benefits and risks of intravenous iron: A systematic review and meta-analysis

Transfusion

Volumn 47, Issue 10, 2007, Pages 1905-1918

  Notebaert, Éric ^a   Chauny, Jean Marc ^b   Albert, Martin ^b   Fortier, Simon ^b   Leblanc, Nancy ^b   Williamson, David R ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FERROUS SULFATE; HEMOGLOBIN; IRON DEXTRAN; IRON SACCHARATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; BLOOD ANALYSIS; BLOOD OXYGEN TENSION; BRADYCARDIA; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FERRITIN BLOOD LEVEL; FEVER; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INTESTINE ABSORPTION; META ANALYSIS; NAUSEA; PARESTHESIA; RASH; RETICULOCYTE COUNT; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SHOCK; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TRANSFERRIN BLOOD LEVEL; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT;

ANEMIA; ENTERAL NUTRITION; FERRITINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SAFETY;

EID: 34548833557     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01415.x     Document Type: Review

References (77)

1. KDOQI. National Kidney Foundation II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006 47 : S16 85.
2. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002 288 : 2827 35.
3. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts - blood transfusion. N Engl J Med 1999 340 : 438 47.
4. Lichtin A. The ASH/ASCO clinical guidelines on the use of erythropoietin. Best Pract Res Clin Haematol 2005 18 : 433 8.
5. Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989 321 : 1163 8.
6. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts - blood conservation. N Engl J Med 1999 340 : 525 33.
7. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000 96 : 823 33.
8. Georgopoulos D, Matamis D, Xirouchaki N, Routsi C, Michalopoulos A, Maggina A, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Vasiliadou G, Peftoulidou M, Maniati A. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 2005 9 : R508 15. Epub 2005 Aug. 5.
9. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995 26 : 41 6.
10. Lapointe M. Iron supplementation in the intensive care unit: when, how much, and by what route? Crit Care 2004 8 (Suppl. 2 S37 41.
11. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Phys India 2003 51 : 170 4.
12. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005 100 : c55 62.
13. Major A, Mathez-Loic F, Rohling R, Gautschi K, Brugnara C. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 1997 98 : 292 4.
14. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients. North Am Clin Trial Am J Kidney Dis 1999 33 : 471 82.
15. Olijhoek G, Megens JG, Musto P, Nogarin L, Gassmann-Mayer C, Vercammen E, Hayes-Licitra SA. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001 41 : 957 63.
16. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001 16 : 967 74.
17. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000 28 : 2773 8.
18. Sengolge G, Horl WH, Sunder-Plassmann G. Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 2005 35 (Suppl 3 46 51.
19. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002 22 : 479 87.
20. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999 33 : 464 70.
21. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002 61 : 1830 9.
22. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000 36 : 88 97.
23. Bullen JJ, Leigh LC, Rogers HJ. The effect of iron compounds on the virulence of Escherichia coli for guinea-pigs. Immunology 1968 15 : 581 8.
24. Elin RJ, Wolff SM. The role of iron in nonspecific resistance to infection induced by endotoxin. J Immunol 1974 112 : 737 45.
25. Gutteridge JM, Quinlan GJ, Evans TW. Transient iron overload with bleomycin detectable iron in the plasma of patients with adult respiratory distress syndrome. Thorax 1994 49 : 707 10.
26. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998 9 : 655 63.
27. Rudd MJ, Good MF, Chapman DE, Powell LW, Halliday JW. Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytes. Immunol Cell Biol 1990 68 : 317 24.
28. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002 40 : 1005 12.
29. van der Kraaij AM, Mostert LJ, van Eijk HG, Koster JF. Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant(+)-cyanidanol-3 and deferoxamine. Circulation 1988 78 : 442 9.
30. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003 64 : 572 8.
31. Caroline L, Rosner F, Kozinn PJ. Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood 1969 34 : 441 51.
32. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998 9 : 869 76.
33. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000 15 : 1827 34.
34. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rev 1984 64 : 65 102.
35. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999 340 : 409 17.
36. Twomley KM, Rao SV, Becker RC. Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. J Thromb Thrombol 2006 21 : 167 74.
37. Chalmers TC, Smith H Jr., Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981 2 : 31 49.
38. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 : 1 12.
39. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999 354 : 1896 900.
40. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995 16 : 62 73.
41. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005 100 : 2503 9.
42. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004 22 : 1301 7.
43. Cuenca J, Garcia-Erce JA, Martinez AA, Solano VM, Molina J, Munoz M. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg 2005 125 : 342 7.
44. Cuenca J, Garcia-Erce JA, Munoz M, Izuel M, Martinez AA, Herrera A. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: a pilot study. Transfusion 2004 44 : 1447 52.
45. Martin Espejo JL, Barbosa Martin F, Galeano Macias R, Soler Junco L. Corregir la anemia en predialisis con dos tipos de hierro intravenoso. Estudio comparativo entre el hierro gluconato (Ferrlecit) vs hierro sacarosa (Venofer). Rev Soc Esp Enferm Nefrol 2004 7 : 16 21.
46. Al-Momen AK, Huraib SO, Mitwalli AH, Al-Wakeel J, Al-Yamani MJ, Abu-Aisha H, Said R. Intravenous iron saccharate in hemodialysis patients receiving r-HuEPO. Saudi J Kidney Dis Transplant 1994 5 : 168 72.
47. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000 11 : 530 8.
48. Bolanos L, Castro P, Falcon TG, Mouzo R, Varela JM. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 2002 22 : 67 72.
49. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001 38 : 988 91.
50. Kao HH, Chen KS, Tsai CJ, Lee CC, Chang HY. Clinical characteristic of parenteral iron supplementation in hemodialysis patients receiving erythropoietin therapy. Chang Gung Med J 2000 23 : 608 13.
51. Roe DJ, Harford AM, Zager PG, Wiltbank TB, Kirlin L, Della Valle AM, Van Wyck DB. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. Am J Kidney Dis 1996 28 : 855 60.
52. Kooistra MP, Kersting S, Gosriwatana I, Lu S. Nijhoff-Schutte J, Hider RC, Marx JJ. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002 32 (Suppl 1 36 41.
53. Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant 2004 19 : 1576 80.
54. Seligman PA, Dahl NV, Strobos J, Kimko HC, Schleicher RB, Jones M, Ducharme MP. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 2004 24 : 574 83.
55. Sunder-Plassmann G, Horl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996 11 : 1797 802.
56. Swedberg B. A clinical investigation of an iron-poly (sorbitol-gluconic acid) complex, Ferastral, for the treatment of iron deficiency anaemia. Scand J Haematol Suppl 1977 32 : 260 8.
57. Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, Zimmermann R, Eckstein R. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion 1999 39 : 465 72.
58. Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 2004 96 : c63 66.
59. Silva J, Andrade S, Ventura H, Santos JP, Colaço S, Oliveira C, Ponce P. Iron supplementation in haemodialysis - practical clinical guidelines. Nephrol Dial Transplant 1998 13 : 2572 7.
60. Norton JA, Peters ML, Wesley R, Maher MM, Brennan MF. Iron supplementation of total parenteral nutrition: a prospective study. JPEN J Parenter Enteral Nutr 1983 7 : 457 61.
61. Burns DL, Mascioli EA, Bistrian BR. Effect of iron-supplemented total parenteral nutrition in patients with iron deficiency anemia. Nutrition 1996 12 : 411 5.
62. Madi-Jebara SN, Sleilaty GS, Achouh PE, Yazigi AG, Haddad FA, Hayek GM, Antakly MC, Jebara VA. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth 2004 18 : 59 63.
63. Rohling RG, Zimmermann AP, Breymann C. Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. J Hematother Stem Cell Res 2000 9 : 497 500.
64. Rosenthal R. The "file-drawer" problem and tolerance for null results. Psychol Bull 1979 86 : 638 41.
65. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998 79 : 299 305.
66. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999 34 : S40 6.
67. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996 50 : 1694 9.
68. Park L, Uhthoff T, Tierney M, Nadler S. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 1998 31 : 835 40.
69. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996 72 : 413 7.
70. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996 11 : 1079 83.
71. Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis: New Dimensions Treatment Anaemia 1992 3 : 71 5.
72. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995 10 : 2070 6.
73. Sunder-Plassmann G, Horl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf 1997 17 : 241 50.
74. Hoigne R, Breymann C, Kunzi UP, Brunner F. [Parenteral iron therapy: problems and possible solutions]. Schweiz Med Wochenschr 1998 128 : 528 35.
75. Bullen JJ, Spalding PB, Ward CG, Rogers HJ. The role of Eh, pH and iron in the bactericidal power of human plasma. FEMS Microbiol Lett 1992 73 : 47 52.
76. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002 32 (Suppl 1 42 9.
77. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG Ferlecit Investigators. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003 63 : 217 24.